US 11,299,788 B2 · Method for the quantification of Faecalibacterium prausnitzii phylogroup I and/or phylogroup II members and the use thereof as biomarkers

Abstract

The present invention relates to a novel method for an accurate quantification in intestinal samples of Faecalibacterium prausnitzii phylogroup I members (PHGI) and/or Faecalibacterium prausnitzii phylogroup II members (PHGII). It further relates to a method for detecting intestinal diseases, including the screening, diagnosis, differential diagnosis, and/or monitoring of disease activity or progression in a human subject comprising determining the abundance of PHGI and/or PHGII in an intestinal sample from said subject. Moreover, it relates to a method for the prediction of the efficacy of a drug in the therapeutic treatment of an intestinal disease in a human subject comprising determining the abundance of PHGI and/or PHGII in an intestinal sample from said subject.

Claims15

Dependent claims

An in vitro method for determining the abundance of one or more of (a) Faecalibacterium prausnitzii phylogroup I members (PHGI) and (b) Faecalibacterium prausnitzii phylogroup II members (PHGII) in an intestinal sample from a subject by quantitative Polymerase Chain Reaction (qPCR) comprising F. prausnitzii 16S rRNA gene amplification comprising using:

(i) F. prausnitzii species-specific 16S rRNA gene primers;
and
(ii) (a) a PHGI-specific probe consisting of the nucleotide sequence of SEQ ID NO:3 for determining the abundance of PHGI;
and/or
(b) a PHGII-specific probe consisting of the nucleotide sequence of SEQ ID NO:4 for determining the abundance of PHGII.

2 more elements

Dependencies are inferred from the claim text.

Facts

Application

15/751,805Filed 11 Aug 2016

Priority

EP 1538242711 Aug 2015

Published

US 2019/0024146 A124 Jan 2019

Granted

12 Apr 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification10 codes

C12Q 1/689
For detection or identification of organisms: for bacteria
C12Q 1/6883
Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes: for diseases caused by alterations of genetic material
C12Q 1/6886
For diseases caused by alterations of genetic material: for cancer
C12Q 2600/106
Oligonucleotides characterized by their use: pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Method for the quantification of Faecalibacterium prausnitzii phylogroup I and/or phylogroup II members and the use thereof as biomarkers

Life of this patent

Method for the quantification of Faecalibacterium prausnitzii phylogroup I and/or phylogroup II members and the use thereof as biomarkers

Life of this patent

Abstract

Claims15